Most advanced TB vaccine fails to boost protection, study finds
By Bloomberg News
This article was published February 4, 2013 at 7:16 a.m.
The most advanced tuberculosis vaccine in 90 years failed to boost protection against the deadly disease when added to the shot given routinely to children, in a setback to the quest for global TB control.
In a study among 2,797 babies in South Africa, those who received the experimental MVA85A vaccine in addition to the standard Bacille Calmette-Guerin shot were no less likely to become infected with the TB bacterium or develop the disease after three years than those who only got the BCG vaccine, researchers from the University of Oxford and the University of Cape Town wrote in The Lancet journal Monday.
The findings deal a blow to researchers looking for a new TB vaccine to improve on BCG, which was introduced in 1921 and is only partially effective against the world’s second-biggest infectious killer.
Comments on: Most advanced TB vaccine fails to boost protection, study finds
To report abuse or misuse of this area please hit the "Suggest Removal" link in the comment to alert our online managers. Read our Terms of Use policy.
You must login to make comments.